Exclusive Summary

• - Single-dose, long-acting uterotonic for C-sections reduces rescue medications and nursing resources, ideal for routine hospital procurement.
• - Core patents have expired while heat-stable IP persists; refrigerated carbetocin can be rapidly registered and distributed across many markets.
• - ~140M births/year with ~28M C-sections; strong, predictable demand for PPH prophylaxis.
• - No US approval and low penetration in several emerging markets create first-entry/tender replacement opportunities.
• - Generics typically offer 20–60% price savings vs originator and win tenders with validated cold-chain and ICH stability data.